NASDAQ:XCUR - Nasdaq - US30205M3097 - Common Stock - Currency: USD
NASDAQ:XCUR (4/21/2025, 12:00:44 PM)
9.9
+1.46 (+17.3%)
The current stock price of XCUR is 9.9 USD. In the past month the price decreased by -37.76%. In the past year, price increased by 200.89%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 16.85 | 301.62B | ||
AMGN | AMGEN INC | 13.83 | 147.42B | ||
GILD | GILEAD SCIENCES INC | 22.55 | 129.60B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1663.62 | 124.03B | ||
REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
ARGX | ARGENX SE - ADR | 323.94 | 36.79B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.31B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.66B | ||
NTRA | NATERA INC | N/A | 19.36B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.41B | ||
BIIB | BIOGEN INC | 7.07 | 17.04B |
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 6 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
EXICURE INC
2430 N. Halsted St.
Chicago ILLINOIS 60614 US
CEO: David A. Giljohann
Employees: 5
Company Website: https://www.exicuretx.com/
Investor Relations: http://investors.exicuretx.com/overview/default.aspx
Phone: 18476731700
The current stock price of XCUR is 9.9 USD. The price increased by 17.3% in the last trading session.
The exchange symbol of EXICURE INC is XCUR and it is listed on the Nasdaq exchange.
XCUR stock is listed on the Nasdaq exchange.
EXICURE INC (XCUR) has a market capitalization of 62.57M USD. This makes XCUR a Micro Cap stock.
EXICURE INC (XCUR) currently has 5 employees.
EXICURE INC (XCUR) has a support level at 8.43 and a resistance level at 14.28. Check the full technical report for a detailed analysis of XCUR support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XCUR does not pay a dividend.
EXICURE INC (XCUR) will report earnings on 2025-06-16.
EXICURE INC (XCUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.15).
The outstanding short interest for EXICURE INC (XCUR) is 3.25% of its float. Check the ownership tab for more information on the XCUR short interest.
ChartMill assigns a technical rating of 2 / 10 to XCUR. When comparing the yearly performance of all stocks, XCUR is one of the better performing stocks in the market, outperforming 98.42% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to XCUR. XCUR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months XCUR reported a non-GAAP Earnings per Share(EPS) of -4.15. The EPS decreased by -45.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -64.43% | ||
ROE | -143.25% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to XCUR. The Buy consensus is the average rating of analysts ratings from 6 analysts.